상세 보기
First-line (1L) trastuzumab deruxtecan (T-DXd) plus rilvegostomig (rilve) plus fluoropyrimidine (FP) in HER2-positive (HER2+) gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): DESTINY-Gastric03 (DG-03) Part 4 arm A results
- Janjigian, Yelena Y.;
- van Laarhoven, Hanneke;
- Shoji, Hirokazu;
- Wyrwicz, Lucjan;
- Lonardi, Sara;
- ... Lee, Jeeyun;
- 외 13명
Citations
WEB OF SCIENCE
0- 제목
- First-line (1L) trastuzumab deruxtecan (T-DXd) plus rilvegostomig (rilve) plus fluoropyrimidine (FP) in HER2-positive (HER2+) gastric cancer (GC), gastroesophageal junction adenocarcinoma (GEJA), or esophageal adenocarcinoma (EA): DESTINY-Gastric03 (DG-03) Part 4 arm A results
- 저자
- Janjigian, Yelena Y.; van Laarhoven, Hanneke; Shoji, Hirokazu; Wyrwicz, Lucjan; Lonardi, Sara; Karaszewska, Boguslawa; Liang, Xinjun; Ferrandiz, Aitana Calvo; Kwiatkowski, Mariusz; Lee, Keun-Wook; Liu, Tianshu; Shitara, Kohei; Rha, Sun Young; Siena, Salvatore; Rabbie, Roy; Lloyd, Caron; Scott, Megan; Lambert, Arthur W.; Lee, Jeeyun
- 발행일
- 2026-04-17
- 유형
- Meeting Abstract
- 저널명
- Cancer Research
- 권
- 86
- 호
- 8